Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205280 | 0.87 | GSK3B (0.80) | GSK3BPTPN1 | |
| SCHEMBL3379031 | 0.81 | GSK3B (0.64) | GSK3BPTPN1CYP3A4KMT2AMAPT | |
| SCHEMBL689331 | 0.80 | GSK3B (0.83) | GSK3BPTPN1LMNACYP1A2KDM4E | |
| SCHEMBL28594745 | 0.80 | GSK3B (0.70) | GSK3BPTPN1LMNAMAPTPKM | |
| SCHEMBL11365527 | 0.80 | MAPT (0.56) | PTPN1LMNACYP1A2CYP3A4MAOA | |
| SCHEMBL1311272 | 0.79 | L3MBTL1 (0.50) | LMNAMAPTTDP1 | |
| SCHEMBL3373429 | 0.78 | LMNA (0.47) | LMNACYP1A2CYP3A4MAOAMEN1 | |
| SCHEMBL70930 | 0.78 | GSK3B (1.00) | GSK3BPTPN1 | |
| SCHEMBL9547546 | 0.78 | LMNA (0.47) | GSK3BLMNACYP1A2CYP3A4MAOA | |
| SCHEMBL3181886 | 0.78 | LMNA (0.47) | LMNACYP1A2CYP3A4MAOAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108383830-B | Acridone stable isotope sulfhydryl compound marking reagent and synthesis method and application thereof | 曲阜师范大学 | 2020-01-10 | — | — | CN | claimed |
| US-8354444-B2 | Substituted pyrrolidine-2-carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-01-15 | — | — | US | claimed |
| EP-2340021-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | claimed |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | US | claimed |
| WO-2010031713-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | claimed |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | DING QINGJIE | 2010-03-25 | — | — | US | claimed |
| WO-2026090173-A1 | MODIFIED SELF-IMMOLATING MOIETIES IN ANTIBODY-DRUG CONJUGATES | CODEABLE THERAPEUTICS, INCORPORATED (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260070898-A1 | PROCESS FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | GLIOBLASTOMA FOUND INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20240352007-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL (CH) | 2024-10-24 | — | — | US | disclosed |
| EP-3615529-B1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BASILEA PHARMACEUTICA INT AG ALLSCHWIL (CH) | 2024-06-05 | — | — | EP | disclosed |
| US-11891382-B2 | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof | Basilea Pharmaceutica International AG | 2024-02-06 | — | — | US | disclosed |
| CN-116947836-A | Method for preparing furazanobenzimidazole and crystal forms thereof | 巴斯利尔药物国际股份公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-110536890-B | Method for preparing furazanobenzimidazole and crystal forms thereof | 巴斯利尔药物国际股份公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2007067993-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067994-A1 | INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070065841-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | ENERGY, U.S. DEPARTMENT OF | 2007-03-22 | — | — | US | disclosed |
| US-20060030543-A1 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | KALYPSYS, INC. | 2006-02-09 | — | — | US | disclosed |
| WO-2005123089-A2 | MULTICYCLIC SULFONAMIDE COMPOUNDS AS INHIBITORS OF HISTONE DEACETYLASE FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-4716169-A | INOTROPIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1987-12-29 | — | — | US | disclosed |
| EP-0185345-A1 | Imidazo derivatives, their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1986-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030543-A1 | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | HDAC6, HDAC3, HDAC5 | GSK3B 153/4885PTPN1 2749/4885LMNA 1450/4885 |
| US-11891382-B2 | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof | FANCI, CYP2F1, CYP4F3 | GSK3B 2920/4885PTPN1 2720/4885LMNA 2122/4885 |
| US-20100152190-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | GSK3B 4011/4885PTPN1 3496/4885LMNA 3002/4885 |
| US-20240352007-A1 | PROCESSES FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | FANCI, FANCD2, CYP2F1 | GSK3B 2890/4885PTPN1 1875/4885LMNA 2020/4885 |
| US-20260070898-A1 | PROCESS FOR THE PREPARATION OF FURAZANOBENZIMIDAZOLES AND CRYSTALLINE FORMS THEREOF | BRCA1, PRKDC, KIT | GSK3B 946/4885PTPN1 1653/4885LMNA 143/4885 |
| US-20070065841-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | POLRMT, FBL, POLL | GSK3B 3452/4885PTPN1 3866/4885LMNA 548/4885 |
| US-20100075948-A1 | Substituted Pyrrolidine-2-Carboxamides | ARG2, CCNY, PYCR1 | GSK3B 4011/4885PTPN1 3496/4885LMNA 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.